| BDB-001 Phase III Trial in ANCA-Associated Vasculitis (NCT07168161) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2025-11-10 |
| To Evaluate The Safety and Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome (NCT07208591) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2025-10-31 |
| A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NCT06975748) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2025-06-12 |
| A Study to Evaluate the Safety and Tolerability of Single and Multiple Dose of STSP-0902 in Healthy Subjects (NCT06948799) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2025-05-08 |
| A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects (NCT06597422) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2024-10-20 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STSP-0902 in Healthy Subjects (NCT06563713) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2024-07-31 |
| Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor (NCT06289166) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2024-03-18 |
| To Evaluate The Safety and Initial Efficacy of STSA-1002 Injection in Patients With Acute Respiratory Distress Syndrome (NCT06038916) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2023-12-09 |
| The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects (NCT06148389) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2023-11-16 |
| A Study of STSA-1201 in Healthy Subjects (NCT05986877) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2023-08-04 |
| To Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B (NCT05760781) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2023-04-25 |
| Evaluate the Safety and Efficacy of STSG-0002 Injection in Patients With Chronic Hepatitis B (NCT05760703) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2023-04-25 |
| The Safety and Tolerability of STSA-1002 Following Subcutaneous Injection in Healthy Subjects (NCT05702983) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2023-01-31 |
| Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor (NCT05619926) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2023-01-09 |
| A Study of STSA-1002 Combined With STSA-1005 in Healthy Subjects (NCT05559125) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2022-11-08 |
| A Study of STSA-1002 in Healthy Subjects (NCT05497635) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2022-10-14 |
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis (NCT05197842) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2022-02-22 |
| The Safety of STSA-1002 Following Intravenous Infusion in Healthy Subjects (NCT05166837) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2022-01-10 |
| A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor (NCT05027230) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2021-10-12 |
| The Safety and Tolerability of STSA-1002 Following Intravenous Infusion in Healthy Subjects (NCT05032144) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2021-09-28 |
| Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (NCT05093855) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2021-08-18 |
| Safety and Efficacy Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) (NCT05103423) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2021-06-24 |
| Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS (NCT04449588) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2020-07-23 |
| Tolerability and Safety of BDB-001 Injection in Healthy Subjects (NCT05361005) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2020-03-12 |
| A Safety and Tolerability Study of BDB-001 in Mild, Moderate COVID-19 Patients (NCT05075304) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2020-02-21 |
| A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor (NCT04747964) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2020-01-15 |
| Safety and Tolerability of BDB-001 Injection in Healthy Subjects (NCT05360927) | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 2019-09-25 |